Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Alliance Pharma said it expected revenues to rise by more than fifth in the first half of the year amid growth from its consumer healthcare products.
For the first half of 2019 revenues were expected to rise 29% to £70.3m from a year earlier and up 28% on a constant currency basis. Excluding acquisitions, revenues increased 10% on a constant currency basis on the same period last year.
Its International Star brands saw healthy revenue growth with sales of £30.9m, up 79% compared with the same period last year and up 21% on a like-for-like basis. 'This growth was underpinned by the continued growth of Kelo-cote with sales up 20% at £13.1m (H1 2018: £10.9m), reflecting continued demand in the Asia Pacific region,' the company said.
'Revenues generated by our Local brands in the first half were approximately £39.4m, an increase of 6% on the same period last year (H1 2018: £37.2m),' it added.
Based on trading in the year to date, the company said expected revenue and underlying trading profit for the full year to be in line with expectations.
'We have seen continued momentum in our business during the first half of 2019, with sales up 29% compared with the previous year and growth coming largely from our consumer healthcare products, which now account for over half of our portfolio,' said Peter Butterfield, Chief Executive Officer of Alliance Pharma.
At 9:36am: (LON:APH) Alliance Pharma PLC share price was +1.3p at 68.4p